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EXPERIMENTAL STUDIES
Antioxidant Vitamins Attenuate
Oxidative Stress and Cardiac Dysfunction
in Tachycardia-Induced Cardiomyopathy
Junya Shite, MD,* Fuzhong Qin, MD, PHD,* Weike Mao, MD,* Hiroya Kawai, MD,*
Suzanne Y. Stevens, PHD,† Chang-seng Liang, MD, PHD, FACC*
Rochester, New York
OBJECTIVES We administered antioxidant vitamins to rabbits with pacing-induced cardiomyopathy to
assess whether antioxidant therapy retards the progression of congestive heart failure (CHF).
BACKGROUND Although oxidative stress is increased in CHF, whether progression of heart failure could be
prevented or reduced by antioxidants is not known.
METHODS Rabbits with chronic cardiac pacing and sham operation were randomized to receive a
combination of beta-carotene, ascorbic acid and alpha-tocopherol, alpha-tocopherol alone or
placebo over eight weeks. Echocardiography was used to measure cardiac function weekly.
Resting hemodynamics and in vivo myocardial beta-adrenergic responsiveness were studied at
week 8. Animals were then sacrificed for measuring myocardial beta-receptor density,
norepinephrine (NE) uptake-1 site density, sympathetic neuronal marker profiles, tissue-
reduced glutathione/oxidized glutathione (GSH/GSSG) ratio and oxidative damage of
mitochondrial DNA (mtDNA).
RESULTS Rapid cardiac pacing increased myocardial oxidative stress as evidenced by reduced myocar-
dial GSH/GSSG ratio and increased oxidized mtDNA and produced cardiac dysfunction,
beta-adrenergic subsensitivity, beta-receptor downregulation, diminished sympathetic neu-
rotransmitter profiles and reduced NE uptake-1 carrier density. A combination of antioxidant
vitamins reduced the myocardial oxidative stress, attenuated cardiac dysfunction and
prevented myocardial beta-receptor downregulation and sympathetic nerve terminal dysfunc-
tion. Administration of alpha-tocopherol alone produced similar effects, but the effects were
less marked than those produced by the three vitamins together. Vitamins produced no effects
in sham-operated animals.
CONCLUSIONS Antioxidant vitamins reduced tissue oxidative stress in CHF and attenuated the asso-
ciated cardiac dysfunction, beta-receptor downregulation and sympathetic nerve terminal
abnormalities. The findings suggest that antioxidant therapy may be efficacious in human
CHF. (J Am Coll Cardiol 2001;38:1734–40) © 2001 by the American College of
Cardiology
Increased production of oxygen free radicals and decreased
oxidant capacity occur in congestive heart failure (CHF)
(1–4). This pro-oxidant shift in the intracellular redox state
may induce cell death by either direct cell membrane
damage by lipid peroxidation (5) or apoptosis through
activation of transcription factors (6). These changes occur
not only in cardiomyocytes but also in cardiac sympathetic
nerves, which are very sensitive to oxidative damage (7).
The purpose of this study was to determine the functional
importance of oxidative stress in animals with CHF by
administering antioxidant vitamins (beta-carotene, ascorbic
acid and alpha-tocopherol). Antioxidant vitamins have been
shown to reduce oxidative stress in the heart produced by
norepinephrine (NE) and prevent the NE-induced myocar-
dial beta-adrenergic subsensitivity, myocyte apoptosis and
noradrenergic nerve terminal dysfunction (8,9). To deter-
mine whether these vitamins also reduce oxidative stress and
attenuate the deterioration of left ventricular (LV) mechan-
ical function and cardiac noradrenergic nerve dysfunction in
CHF (10,11) we carried out this study using a rapid cardiac
pacing model, which is known to increase oxygen free
radical production (12). We administered either a combi-
nation of antioxidant vitamins (beta-carotene, ascorbic acid
and alpha-tocopherol) or alpha-tocopherol alone to animals
with CHF and sham-operated animals for eight weeks. The
results were compared with those of placebo-treated ani-
mals. We measured global cardiac function, myocardial
beta-receptor density, NE uptake-1 site density and cardiac
sympathetic nerve transmitter profiles. To assess the anti-
oxidant effects of vitamins we measured cardiac tissue-
reduced glutathione/oxidized glutathione (GSH/GSSG)
ratio and mitochondrial DNA (mtDNA) 8-oxo-7,8-
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dihydro-2-deoxyguanosine (8-oxo-dG), a sensitive, stable
marker of oxidative stress in cellular DNA (13).
METHODS
Experimental model. This study was approved by the
University of Rochester Committee on Animal Resources
and conformed to the guiding principles approved by the
Council of the American Physiological Society and Na-
tional Institutes of Health Guide for the Care and Use of
Laboratory Animals (DHHS Publication No. [NIH] 85-
23, Revised 1985, Office of Science and Health Reports).
Congestive heart failure was induced in adult New
Zealand White rabbits (2.8 to 3.6 kg) using a modified rapid
cardiac pacing technique (11). Briefly, subxyphoid thora-
cotomy and pericardiotomy were performed under isoflu-
rane gas anesthesia. Two shielded pacing leads (TPW50,
Ethicon, Inc., Somerville, New Jersey) were sutured onto
the LV apex and left pectoral muscle, respectively, and
exteriorized to the interscapular region. One week later,
animals were randomly assigned to receive pacing at a rate
of 360 beats/min with a modified implantable program-
mable pacemaker (Model 8086 Prevail, Medtronic Inc.,
Minneapolis, Minnesota) (animals with CHF) or no cardiac
pacing (sham animals).
Experimental protocol. The animals with CHF and sham
animals were each divided into three groups according to
the vitamin regimens: 1) beta-carotene, 20 mg; ascorbic
acid, 200 mg and alpha-tocopherol, 200 mg; 2) alpha-
tocopherol, 200 mg; and 3) placebo. The doses were
designed to infuse evenly over eight weeks using subcuta-
neous pellets (Innovative Research of America, Sarasota,
Florida). Animals were examined for clinical evidence of
heart failure and echocardiographic changes of LV mechan-
ical function. After eight weeks of cardiac pacing, pacing
was discontinued, and the animals were anesthetized for
measuring arterial blood NE, resting hemodynamics and
cardiac inotropic responses to isoproterenol. The animals
were then sacrificed with intravenous sodium pentobarbital
(100 mg/kg). The heart was removed and weighed and
rinsed in ice-cold oxygenated normal saline. Fresh LV free
wall was taken for measuring glutathione and noradrenergic
nerve terminal transmitter profiles by NE histofluorescence
and tyrosine hydroxylase immunocytochemistry. Remaining
LV tissue was stored in liquid nitrogen for later measure-
ments of myocardial NE uptake-1 carrier sites, beta-
adrenoceptor density and mtDNA 8-oxo-dG.
Echocardiographic and hemodynamic measurements.
Two-dimensional and M-mode echocardiography were ob-
tained using a 5-MHz transducer on a Toshiba Model
SSH-60A sonographic system (Toshiba America Medical
Systems, Tustin, California). Maximal LV end-diastolic
dimension (EDD) and end-systolic dimension (ESD) were
measured and used to calculate LV fractional shortening
(FS) by the following equation: FS  [(EDD  ESD)/
EDD  100].
For the hemodynamic studies, the animals were anes-
thetized with ketamine (35 mg/kg) and midazolam
(0.8 mg/kg). A 20-gauge fluid-filled catheter (Insyte,
Deseret Medical Inc., Becton, Dickinson and Company,
Sandy, Utah) was inserted into the left carotid artery for
measuring aortic pressure, while a 2F micromanometer-
tipped catheter (Millar Instruments Inc., Houston, Texas)
was advanced into the left ventricle via the right carotid
artery for measuring the LV pressures. Electrocardiograms,
aortic pressure and the first derivative of LV pressure
(dP/dt) were recorded on a multichannel recorder (Brush
Model 480, Gould Inc., Instrument Systems Division,
Cleveland, Ohio). At least 1 h was allowed to elapse after
the catheterization before the resting hemodynamic data
were taken in triplicate over a 15 to 20 min steady state. The
measurements were averaged and used for statistical analy-
ses. Two doses of isoproterenol (0.4 and 0.8 g/kg, intra-
venous) were then administered to measure the peak LV
dP/dt response to beta-agonist stimulation. Five consecutive
beats at either baseline or peak response were averaged for
statistical analyses.
Myocardial glutathione measurement. Fresh LV myocar-
dium was homogenized in three volumes of 1% picric acid
and the supernatant collected for measuring total gluta-
thione using a glutathione reductase-coupled enzymatic
assay (14) and a Perkin Elmer Lambda 3 UV/VIS spectro-
photometer (Perkin Elmer, Norwalk, Connecticut). Oxi-
dized glutathione was measured by masking the GSH by
2-vinyl pyridine in the enzymatic assay. The ratio of GSH
to GSSG is a measure of total tissue oxidative stress.
Myocardial mtDNA 8-oxo-dG measurement. Left ven-
tricular muscle samples were prepared for isolation of
mitochondria (15). The mtDNA was extracted using
QIAamp blood kit (Qiagen, Inc., Valencia, California) and
injected into a YMC Basic S 3  column (4.6  150 mm,
Waters Corp., Milford, Massachusetts) in a BAS 480
HPLC (Bioanalytical Systems, Inc., West Lafayette, Indi-
ana) for measuring 8-oxo-dG and 2-deoxyguanosine (dG).
A Model 5200A Coulochem II electrochemical detector
equipped with a Model 5011 analytical cell and Model 5021
Abbreviations and Acronyms
CHF  congestive heart failure
dP/dt  first derivative of LV pressure
dG  2-deoxyguanosine
EDD  end-diastolic dimension
ESD  end-systolic dimension
FS  fractional shortening
GSH  reduced glutathione
GSSG  oxidized glutathione
LV  left ventricular
MI  myocardial infarction
mtDNA  mitochondrial DNA
NE  norepinephrine
8-oxo-dG  8-oxo-7,8-dihydro-2-deoxyguanosine
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guard cell (ESA, Inc., Chelmsford, Massachusetts) was used
(16).
Myocardial beta-adrenoceptor density and NE uptake-1
carrier site density. Left ventricular beta-adrenoceptor
density and NE uptake-1 carrier site density were measured
by the radioligand binding technique using [125I]-
iodocyanopindolol (17) and [3H] nisoxetine (11) (NEN
Life Science Products, Inc., Boston, Massachusetts), respec-
tively. The radioactivity was counted in a Tri-Carb 2400
TR liquid scintillation spectrometer (Packard Instrument,
Downers Grove, Illinois). The number of receptor binding
sites and dissociation constants were calculated using the
EBDA computer software program (Elsevier Science, Cam-
bridge, United Kingdom) (18).
Cardiac sympathetic nerve terminal neurotransmitter
profiles. Cardiac sympathetic nerve profiles were assessed
by histofluorescence for catecholamines and immunocyto-
chemistry for tyrosine hydroxylase using sucrose-potassium
phosphate-glyoxylic acid and sheep anti-tyrosine hydroxy-
lase primary antibody, respectively (10). Tissue sections
were photographed onto 35-mm slides with 30 magnifi-
cation. The numbers of catecholaminergic profiles and
tyrosine hydroxylase profiles were counted morphometri-
cally in 0.003536 mm3 and 0.00885 mm3 fields, respec-
tively. At least six fields were counted for each animal and
the results averaged.
Statistical analysis. Results are expressed as means 
SEM. Student t test was used to determine the difference
between the sham rabbits and the rabbits with CHF.
Analysis of variance (ANOVA) and post hoc Tukey com-
parison test was used to determine the statistical significance
of differences among the three groups with CHF (treated
with the three vitamin combination, alpha-tocopherol alone
or placebo) and sham animals. For the serial echocardio-
graphic data, ANOVA for repeated measures was used to
determine the effects of pacing and vitamin treatment. A
probability value of 0.05 was considered significant.
RESULTS
Clinical manifestations of CHF and resting hemody-
namics. Body weight, heart weight and resting hemody-
namics are shown in Table 1. In the sham-operated animals,
there were no differences in any of the parameters between
the placebo- and vitamin-treated groups. Chronic rapid
cardiac pacing increased right atrial pressure and LV end-
diastolic pressure and decreased mean aortic pressure and
LV dP/dt. Animals with CHF exhibited decreased mobility
and fluid retention (pleural effusion: 1.5  0.4 ml; ascites:
10.3  4.3 ml). There was a small, though statistically
insignificant, increase in heart weight in animals with CHF
compared with the sham animals. Administration of three
antioxidant vitamins had no effects on body weight, heart
rate, mean aortic pressure, right atrial pressure or LV
end-diastolic pressure but improved resting LV dP/dt in
animals with CHF. A qualitatively similar change occurred
in LV dP/dt after alpha-tocopherol treatment alone, but the
change was smaller than that produced by three antioxidant
vitamins and did not reach statistical significance compared
with the placebo-treated animals with CHF. Table 1 also
shows that arterial NE concentration was increased in
animals with CHF. Administration of vitamins did not
affect arterial NE concentration in either sham animals or
animals with CHF.
Serial echocardiographic changes in developing CHF.
Figure 1 shows that rapid cardiac pacing caused a progres-
sive increase in LV EDD (F  41.56, p  0.001) and a
decrease in LV FS (F  25.26, p  0.0001) and that
administration of antioxidant vitamins attenuated the in-
crease of EDD and a decrease of FS in animals with CHF
(triple vitamins: LVEDD: F  5.46, p  0.0001, FS: F 
4.45, p  0.0001; alpha-tocopherol: LVEDD: F  2.28,
p  0.026, FS: F  2.74, p  0.008). Compared to triple
vitamins, vitamin E alone produced a smaller effect on FS in
animals with CHF (F  3.75, p  0.001).
Table 1. Weights and Resting Hemodynamics in Sham and Pacing-Induced Rabbits With
Heart Failure
Sham CHF
Placebo Vitamins Placebo Vitamins Vitamin E
Number of animals 11 10 10 10 8
BW (kg) 3.1  0.1 3.2  0.1 3.2  0.1 3.1  0.1 3.1  0.1
HW (g) 7.1  0.3 6.3  0.2 7.8  0.3 7.3  0.3 7.9  0.2
HR (beats/min) 257  9 264  8 251  11 248  11 253  7
MABP (mm Hg) 98  3 97  3 86  3* 98  5 95  3
RAP (mm Hg) 2.0  0.4 2.2  0.2 6.1  0.8* 5.3  0.6* 5.5  0.6*
LVEDP (mm Hg) 7.2  0.6 7.7  1.1 24.2  1.9* 19.4  1.5* 23.3  1.8*
LVdP/dt (mm Hg/s) 3,530  393 3,650  273 2,010  165* 2,685  181† 2,445  375
Plasma (NE) (pg/ml) 126  14 136  17 391  26* 321  11* 348  25*
*p  0.05 compared with the Sham placebo group; †p  0.05 compared with the CHF placebo group. Values are expressed as
means  SEM.
BW  body weight; CHF  congestive heart failure; HR  heart rate; HW  heart weight; LVEDP  left ventricular
end-diastolic pressure; LVdP/dt  peak left ventricular dP/dt; MABP  mean aortic blood pressure; NE  norepinephrine;
RAP  right atrial pressure.
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LV dP/dt responses to isoproterenol and myocardial
beta-receptor density. Figure 2 shows the changes in peak
LV dP/dt response produced by isoproterenol and myocar-
dial beta-receptor density in sham animals and in animals
with CHF. Isoproterenol produced a marked increase in LV
dP/dt in sham animals. This increase was reduced in
animals with CHF but restored in the animals treated with
the multivitamins. Alpha-tocopherol alone also improved
the LV dP/dt response to isoproterenol, but the magnitude
of effect was smaller than that achieved by the three
vitamins. The difference in the LV dP/dt response between
the CHF placebo and alpha-tocopherol groups was not
statistically significant.
Figure 2 also shows that rapid cardiac pacing-reduced
myocardial beta-receptor density and myocardial beta-
receptor downregulation in CHF was abolished by the
administration of either three antioxidant vitamins or alpha-
tocopherol alone. There were no differences in dissociation
constant among the groups.
Myocardial glutathione and mtDNA 8-oxo-dG. Rapid
cardiac pacing increased myocardial GSSG (0.13 
0.02 mol/g vs. 0.02  0.01 mol/g in sham animals, t 
5.74, p  0.001) and reduced the ratio of GSH to GSSG
([GSH]/[GSSG]) (Fig. 3). It also increased mtDNA
8-oxo-dG (9.0  1.4 pg/g vs. 3.9  0.8 pg/g in sham
animals, t  3.18, p  0.01). Since there was no change in
mtDNA dG, the ratio of mtDNA 8-oxo-dG to dG was also
increased in animals with CHF (Fig. 3). Administration of
beta-carotene, ascorbic acid and alpha-tocopherol had no
effects in sham animals but abolished the changes in
myocardial GSH/GSSG ratio and mtDNA 8-oxo-dG/dG.
Administration of alpha-tocopherol also abolished the in-
crease in mtDNA 8-oxo-dG/dG, but its effect on myocar-
dial GSH/GSSG ratio was less marked than that produced
by the three vitamins together.
Cardiac sympathetic nerve terminal profiles. Figure 4
shows that rapid cardiac pacing reduced cardiac NE
uptake-1 carrier site density and catecholaminergic and
tyrosine hydroxylase immunostained profiles. These
changes in CHF were attenuated by the administration of
beta-carotene, ascorbic acid and alpha-tocopherol. In con-
trast, antioxidant vitamins had no effects on the sympathetic
nerve terminal profiles in sham animals. Furthermore,
although administration of alpha-tocopherol alone pro-
duced qualitatively similar results in animals with CHF, the
magnitude of changes was smaller than those produced by
the three vitamins together.
Figure 1. Serial changes in left ventricular end-diastolic dimension and
fractional shortening in animals with congestive heart failure (CHF) and
sham-operated animals. The changes in sham-operated animals treated
with antioxidant vitamins were the same as in placebo-treated sham
animals. Bars  SEM. *p  0.05 vs. the sham animals; †p  0.05 vs. the
CHF  placebo group; ‡p  0.05 vs. the CHF  vitamins group. The
number of animals in each group is shown in Table 1.
Figure 2. Change in left ventricular (LV) peak positive first derivative of
LV pressure (dP/dt) in response to isoproterenol administration and
myocardial beta-receptor density in sham animals and animals with
congestive heart failure (CHF). Symbols as in Figure 1.
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DISCUSSION
Rapid cardiac pacing produces early LV dilation, which
increases progressively with the duration of pacing along
with the decline of LV mechanical function (11). Left
ventricular systolic dysfunction was evidenced in this study
by an increase in LV end-diastolic pressure, and decreases in
dP/dt and FS, although direct measurement of LV contrac-
tility is lacking. Furthermore, like human cardiomyopathy,
the animals with pacing cardiomyopathy showed increased
plasma NE, beta-receptor downregulation, reduced sympa-
thetic neuronal reuptake of NE and sympathetic nerve
terminal abnormalities. This study extends our earlier ob-
servation of the protective effects of antioxidant vitamins on
sympathetic nerve terminal function (8) to CHF.
Oxidative stress in CHF. The results of this study indicate
that oxidative stress is present in the failing heart. Although
our study does not identify the source of oxidative stress,
oxygen free radicals may be generated from oxidized deriv-
atives of NE (19), ischemic metabolic distress or activated
cytokines such as tumor necrosis factor alpha (20). Our
findings are consistent with the increase of myocardial
thiobarbituric acid reactive substance and immunohisto-
chemical visualization of lipid peroxides in cardiomyocytes
after four weeks of rapid ventricular pacing in dogs (12).
Increased mitochondrial production of superoxide also has
been demonstrated directly using electron spin resonance
spectroscopy in pacing-induced cardiomyopathy (12). Ad-
ditionally, a progressive increase in myocardial lipid peroxi-
dation has been shown to correlate with the severity of heart
failure produced by myocardial infarction (MI) (21).
Antioxidant effects of vitamins in CHF. Effective inhibi-
tion of free radical production was produced by antioxidant
vitamins in our study. Since these agents also attenuated the
cardiac dysfunction and sympathetic nerve terminal abnor-
malities, we speculate that the beneficial actions of the
vitamins on the heart muscle and sympathetic nerve endings
are mediated, at least in part, via their antioxidant effects.
In this study, we chose the three commonly used antiox-
idant vitamins, not only because of their efficacy as antioxi-
dants but also because of their clinical relevance and
minimal toxicity (22). The doses of vitamins chosen for the
study were 3 to 10 times the current recommended dietary
allowances for humans and are within the human therapeu-
Figure 3. Changes in myocardial reduced glutathione/oxidized glutathione
(GSH/GSSG) and mitochondrial DNA (mtDNA) 8-oxo-7,8-dihydro-2-
deoxyguanosine/2-deoxyguanosine (8-oxo-dG/dG) ratios in sham ani-
mals and animals with CHF. Symbols as in Figure 1.
Figure 4. Changes in left ventricular norepinephrine (NE) uptake-1 carrier
site density, catecholaminergic fluorescence profile and tyrosine hydroxy-
lase immunostained profile in sham animals and in animals with congestive
heart failure (CHF). Symbols as in Figure 1.
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tic ranges (23). A similar vitamin regimen raised myocardial
alpha-tocopherol levels 70% in animals (unpublished data).
Alpha-tocopherol is a potent lipophilic antioxidant, located
mainly at the membrane surface (24,25). Beta-carotene is
more lipophilic than alpha-tocopherol and can penetrate
into the cell membrane deeper than alpha-tocopherol. Thus,
beta-carotene is effective in quenching singlet oxygen in
inner cells and complements the action of alpha-tocopherol,
which acts primarily in the cytoplasmic membrane (26). On
the other hand, ascorbic acid is the most important antiox-
idant in extracellular fluids (27). It traps peroxyl radicals in
the aqueous phase and inhibits lipid peroxidation. Ascorbic
acid reacts with tocopheroxyl radicals to yield tocopherol
and an ascorbic radical at the surface of the cell membrane,
thus regenerating reduced tocopherol and transferring the
oxidative challenge to the aqueous phase (28). These syn-
ergistic effects of ascorbic acid, alpha-tocopherol and beta-
carotene may help explain the greater antioxidant effects
of the vitamin mixture compared with that produced by
alpha-tocopherol alone. Furthermore, the fact that alpha-
tocopherol produced greater inhibition of mtDNA
8-oxo-dG than cellular glutathione oxidation in the alpha-
tocopherol alone group is consistent with the lipophilic
property of alpha-tocopherol and suggests the need to
include a hydrophilic antioxidant in an effective antioxidant
treatment regimen. However, despite near complete aboli-
tion of the oxidative stress as judged by the changes in the
tissue GSH/GSSG ratio and mtDNA 8-oxo-dG in the
animals with CHF treated with vitamins, LV mechanical
function remained depressed. These findings suggest that
other factors are operative in the pathogenesis of cardiac
depression in pacing-induced cardiomyopathy. Further-
more, despite the similarities in cardiac hemodynamics,
neurohormonal profiles and oxidative stress between the
pacing-induced cardiomyopathy and human cardiomyopa-
thy, results of this study should be extrapolated with caution
to clinical CHF in which the heart is not artificially paced at
fast rates.
Clinical implications. The information on the effects of
antioxidant vitamins in human CHF is scarce. However,
since a significant correlation exists between the oxidative
stress and the severity of CHF (2,29,30), one may assume
that antioxidant therapy is beneficial. A study of patients
with CHF showed that vitamin E reduces plasma levels of
malondialdehyde and superoxide anion and elevates the
levels of antioxidant enzymes (3).
Combined treatment with vitamins C and E suppressed
neutrophil-mediated free radical production and lowered
blood lipid peroxidation product in patients with acute MI
(31). Oral administration of vitamins A and E for five days
before surgery also reduced the oxidative stress after reper-
fusion with coronary artery bypass grafting (32). Other
studies have shown that vitamin C improves endothelial
function of conduit arteries (33) and prevents nitrate toler-
ance in patients with CHF (34). It also augments the
inotropic response to dobutamine in human subjects with
normal LV ejection fraction (35). Vitamin E reduces coro-
nary atherosclerosis progression using serial angiography
(36). The combination of vitamins A, C and E reduces
infarct size and cardiac events during the first 28 days after
onset of acute MI (37). Collectively, the studies indicate
that the oxidative stress levels contribute to the adrenergic
regulation of vascular tone and ventricular performance.
Administration of antioxidant vitamins may affect the rest-
ing vasomotor tones and adrenergic responses of the blood
vessel and the heart. However, none of the clinical studies
include assessment of cardiac function. The long-term
effects of vitamin E on cardiovascular events have been
studied, but the results are conflicting. In the Cambridge
Heart Antioxidant study (38), vitamin E reduced the
incidence of nonfatal events in patients with coronary
disease over a median follow-up period of 17 months, but
there was a trend to increased mortality. In the Heart
Outcome Prevention Evaluation study, vitamin E adminis-
tered over a longer period exerted no beneficial cardiovas-
cular effects in high-risk subjects, including patients with
coronary artery disease with and without LV dysfunction
(39). Vitamin E supplement also produced no significant
beneficial effects in patient after MI (40). The reasons for
the discrepant results are not known but may relate to the
different patient characteristics and the use of concomitant
medications (41). The role of vitamin E, either alone or in
combination with other antioxidants, in human CHF de-
serves further investigation.
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